Danielle Trancucci

1.5k total citations
14 papers, 135 citations indexed

About

Danielle Trancucci is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Danielle Trancucci has authored 14 papers receiving a total of 135 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 7 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Danielle Trancucci's work include Multiple Myeloma Research and Treatments (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (7 papers). Danielle Trancucci is often cited by papers focused on Multiple Myeloma Research and Treatments (14 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (7 papers). Danielle Trancucci collaborates with scholars based in United States, Spain and Netherlands. Danielle Trancucci's co-authors include Niels W.C.J. van de Donk, Tara Stephenson, María‐Victoria Mateos, Raluca Verona, Ajay K. Nooka, Katherine Chastain, Alfredo Perales‐Puchalt, Arnob Banerjee, Lotfi Benboubker and Alfred L. Garfall and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Danielle Trancucci

13 papers receiving 131 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Danielle Trancucci United States	7	96	89	54	38	20	14	135
Chiara Caraccio United States	4	66 0.7×	58 0.7×	33 0.6×	39 1.0×	33 1.6×	5	106
Idoia Rodríguez Spain	2	84 0.9×	106 1.2×	30 0.6×	60 1.6×	40 2.0×	5	154
Anetta Marcinek Germany	4	74 0.8×	36 0.4×	29 0.5×	28 0.7×	74 3.7×	16	122
Wojciech Janowski Australia	7	107 1.1×	128 1.4×	50 0.9×	76 2.0×	14 0.7×	18	150
Sungwoo Ahn Canada	7	61 0.6×	59 0.7×	29 0.5×	43 1.1×	23 1.1×	17	98
Helen Varsos United States	6	81 0.8×	83 0.9×	15 0.3×	44 1.2×	29 1.4×	15	128
Bettina Brauchle Germany	4	71 0.7×	29 0.3×	30 0.6×	25 0.7×	62 3.1×	12	107
Luca Bertamini Italy	8	94 1.0×	148 1.7×	9 0.2×	124 3.3×	9 0.5×	15	175
Yana Lutska United States	7	96 1.0×	144 1.6×	16 0.3×	112 2.9×	10 0.5×	12	151
Tobias Kampfenkel United States	7	85 0.9×	95 1.1×	16 0.3×	78 2.1×	8 0.4×	27	120

Countries citing papers authored by Danielle Trancucci

Since Specialization

Citations

This map shows the geographic impact of Danielle Trancucci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danielle Trancucci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danielle Trancucci more than expected).

Fields of papers citing papers by Danielle Trancucci

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danielle Trancucci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danielle Trancucci. The network helps show where Danielle Trancucci may publish in the future.

Co-authorship network of co-authors of Danielle Trancucci

This figure shows the co-authorship network connecting the top 25 collaborators of Danielle Trancucci. A scholar is included among the top collaborators of Danielle Trancucci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danielle Trancucci. Danielle Trancucci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Matous, Jeffrey, Albert Oriol, Alfred L. Garfall, et al.. (2024). Higher Teclistamab Step-up Dosing in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Results from the Majestec-1 Trial. Blood. 144(Supplement 1). 4749–4749.

Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). MM-162 Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study. Clinical Lymphoma Myeloma & Leukemia. 23. S477–S477. 2 indexed citations

Martin, Thomas G, María‐Victoria Mateos, Ajay K. Nooka, et al.. (2023). Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC‐1 study of patients with relapsed/refractory multiple myeloma. Cancer. 129(13). 2035–2046. 28 indexed citations

Donk, Niels W.C.J. van de, Philippe Moreau, Alfred L. Garfall, et al.. (2023). POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S224–S224. 3 indexed citations

Sidana, Surbhi, Philippe Moreau, Alfred L. Garfall, et al.. (2023). P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). HemaSphere. 7(S3). e62475d0–e62475d0. 6 indexed citations

Donk, Niels W.C.J. van de, Alfred L. Garfall, Lotfi Benboubker, et al.. (2023). Evaluation of prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) to inform the management of patients (pts) treated with teclistamab in MajesTEC-1.. Journal of Clinical Oncology. 41(16_suppl). 8033–8033. 16 indexed citations

Bhutani, Manisha, Alfred L. Garfall, Katarina Uttervall, et al.. (2023). P881: DURABILITY OF RESPONSES WITH BIWEEKLY DOSING OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA ACHIEVING A CLINICAL RESPONSE IN THE MAJESTEC-1 STUDY. HemaSphere. 7(S3). e90600b0–e90600b0. 1 indexed citations

Donk, Niels W.C.J. van de, Alfred L. Garfall, Lotfi Benboubker, et al.. (2023). P911: EVALUATION OF PROPHYLACTIC TOCILIZUMAB (TOCI) FOR THE REDUCTION OF CYTOKINE RELEASE SYNDROME (CRS) TO INFORM THE MANAGEMENT OF PATIENTS (PTS) TREATED WITH TECLISTAMAB IN MAJESTEC-1. HemaSphere. 7(S3). e43149cb–e43149cb. 3 indexed citations

Usmani, Saad Z., Lionel Karlin, Lotfi Benboubker, et al.. (2023). Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the majesTEC-1 study.. Journal of Clinical Oncology. 41(16_suppl). 8034–8034. 22 indexed citations

10.

Donk, Niels W.C.J. van de, Philippe Moreau, Alfred L. Garfall, et al.. (2023). Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 41(16_suppl). 8011–8011. 35 indexed citations

11.

Donk, Niels W.C.J. van de, Philippe Moreau, Alfred L. Garfall, et al.. (2023). MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) × CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 23. S477–S478. 2 indexed citations

12.

Vishwamitra, Deeksha, Sheri Skerget, Tatiana Perova, et al.. (2023). Longitudinal Correlative Profiles of Responders, Nonresponders, and Those with Relapse on Treatment with Teclistamab in the Phase 1/2 MajesTEC-1 Study of Patients with Relapsed/Refractory Multiple Myeloma. Blood. 142(Supplement 1). 455–455. 8 indexed citations

13.

Nooka, Ajay K., Philippe Moreau, Saad Z. Usmani, et al.. (2022). Teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated efficacy and safety results from MajesTEC-1.. Journal of Clinical Oncology. 40(16_suppl). 8007–8007. 8 indexed citations

14.

Martínez‐López, Joaquín, Philippe Moreau, Saad Z. Usmani, et al.. (2022). P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1. HemaSphere. 6. 811–812. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact